Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Study Summary

The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.

Conditions

Non-small Cell Lung Cancer

Interventions / Drugs

Durvalumab Oleclumab Monalizumab Dato-DXd AZD0171 Carboplatin Cisplatin Pemetrexed/Cisplatin Pemetrexed/Carboplatin Carboplatin/Paclitaxel Volrustomig Rilvegostomig

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment630 participants

Primary Completion—

Lead SponsorAstraZeneca

Data Retrieved2026-04-11 02:55:19.909809+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.